Can active hepatitis C virus infection cause cholestasis?

Can Active Hepatitis C Infection Cause Cholestasis?

Yes, active hepatitis C virus infection can cause cholestasis, though this is recognized as an uncommon manifestation that occurs primarily in specific clinical contexts.

Evidence from Guidelines

The EASL Clinical Practice Guidelines for Management of Cholestatic Liver Diseases 1 explicitly list hepatitis C (along with hepatitis B and E) in their table of typical biliary lesions under "nonsuppurative destructive cholangitis." This guideline recognition establishes that HCV is an acknowledged, albeit unusual, cause of cholestatic liver disease.

Clinical Contexts Where HCV Causes Cholestasis

1. Fibrosing Cholestatic Hepatitis (FCH)

This represents the most severe and well-documented cholestatic presentation of HCV:

• Post-transplant setting: FCH occurs most commonly in immunosuppressed patients after liver transplantation, characterized by rapidly progressive cholestatic hepatitis with marked bile ductular proliferation, ballooned hepatocytes, and periductular fibrosis 2, 3
• Mortality: This form is often fatal, with patients developing severe progressive cholestatic hepatitis and liver failure within 5 months of onset 3
• Immunosuppression link: The use of mycophenolate mofetil (MMF) has been specifically implicated in fatal FCH cases 2
• Rare in immunocompetent patients: While FCH typically requires immunosuppression, rare cases have been reported in immunocompetent individuals 4

2. Intrahepatic Cholestasis of Pregnancy (ICP)

HCV infection significantly increases the risk of cholestatic complications during pregnancy:

• Dramatically elevated risk: Meta-analysis demonstrates a pooled odds ratio of 20.40 (95% CI: 9.39-44.33) for developing ICP in HCV-infected pregnant women compared to non-infected pregnant women 5
• Viral load correlation: HCV-infected patients with ICP have significantly higher median viral loads (495,000 vs. 8,000 copies/ml, P<0.001) compared to HCV-infected pregnant women without ICP 6
• Bidirectional association: Not only does HCV increase ICP risk, but ICP patients also have a 4-fold increased risk of later HCV infection (OR 4.08,95% CI: 3.13-5.31) 5
• Clinical recommendation: Given the high prevalence (45% in one study 6), women with suspected ICP should be tested for HCV infection

3. Acute HCV Infection

Cholestasis can occur during acute hepatitis C, though this is uncommon:

• Acute HCV can present with prolonged jaundice and unusually high serum bilirubin levels 4
• Severe elevation of bile acids (up to 239 micromol/L) has been documented in acute HCV with concurrent ICP 7
• Histology may show marked fibrosis and severe cholestasis mimicking FCH even in acute infection 4

Important Clinical Caveats

Cholestasis is NOT a typical presentation of chronic HCV infection in immunocompetent patients. The natural history of chronic HCV typically involves waxing and waning aminotransferases with little cholestatic features over a 10-year course 2. When cholestasis appears in an HCV-infected patient, consider:

• Immunosuppression status (transplant recipients, immunosuppressive medications)
• Pregnancy (screen for ICP)
• Acute vs. chronic infection (acute infection more likely to present with cholestasis)
• Alternative causes (the EASL guidelines emphasize that primary biliary cirrhosis, primary sclerosing cholangitis, and drug-induced cholestasis are far more common causes of chronic cholestasis 1)

Diagnostic Approach

When evaluating cholestasis in an HCV-infected patient:

• Rule out mechanical obstruction with ultrasound first 1
• Check immunosuppression status and recent medication changes (especially MMF)
• Assess pregnancy status in women of childbearing age
• Measure HCV viral load (higher loads correlate with cholestatic presentations 6)
• Consider liver biopsy if diagnosis remains unclear, looking specifically for bile ductular proliferation, periductular fibrosis, and cholestasis patterns 1, 2

The key clinical message: while HCV can cause cholestasis, this occurs primarily in immunosuppressed patients (especially post-transplant), pregnant women, or during acute infection—not as a typical feature of chronic HCV in immunocompetent individuals.